Chemclin Diagnostics Co 688468.SS · CNY

Its shares trade on Shanghai under the ticker 688468.SS. It has been listed since 9 April 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥332.7m and net income of CN¥44.4m. At that date it held total assets of CN¥1.76bn and shareholders' equity of CN¥1.41bn.

Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sales of vitro diagnostic reagents and instruments for clinical immuno chemiluminescence diagnosis in China. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-04-09. The firm's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The firm mainly operates its businesses in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Yanling HuangChief Financial Officer, Secretary of the Board, Director$820,000
• Mr. Zhengming HuangDeputy General Manager, Director$590,000
• Mr. Weiguo ZhaoDeputy General Manager, Director$402,000
• Mr. Lin LiDirector, since 2022$1.8m
• Ms. Yue RenDirector$849,100
• Mr. Junjie ZhangDirector
• Qi ZhouDirector
• Ms. Na SunIndependent Director$100,000
• Ms. Jie ZhangIndependent Director$100,000
• Mr. Renqian ZhongIndependent Director$100,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.